A bill to increase the clarity and predictability of the process for developing applications for Rx-to-nonprescription switches.

# Summary of S 2529 **What the Bill Does** S 2529 would streamline and clarify the process by which pharmaceutical companies can switch medications from prescription-only to over-the-counter (OTC) status. Currently, the procedure for making these switches can be unclear and unpredictable for drug manufacturers. This bill aims to establish clearer guidelines and timelines so companies know what steps to take and what to expect when requesting that the FDA allow a prescription drug to be sold without a prescription. **Who It Affects** This legislation would primarily benefit pharmaceutical companies seeking to make drugs more accessible to consumers, and patients who might gain easier access to certain medications without needing a doctor's visit or prescription.

The FDA would also be affected, as the bill would likely require the agency to establish more transparent procedures for reviewing these applications. **Current Status** As of now, S 2529 remains in committee and has not yet been voted on by the full Senate. This means it's still in the early stages of the legislative process and may undergo changes before any vote occurs.